Goncalves Zorzella-Pezavento, Sofia Fernanda [UNESP]Chiuso-Minicucci, Fernanda [UNESP]Donega Franca, Thais Graziela [UNESP]Watanabe Ishikawa, Larissa Lumi [UNESP]Rosa, Larissa Camargo da [UNESP]Colavite, Priscila Maria [UNESP]Marques, CamilaValerio Ikoma, Maura RosaneSilva, Celio LopesSartori, Alexandrina [UNESP]2014-12-032014-12-032014-03-15Journal Of Neuroimmunology. Amsterdam: Elsevier Science Bv, v. 268, n. 1-2, p. 35-42, 2014.0165-5728http://hdl.handle.net/11449/112636Most of the therapeutic strategies to control multiple sclerosis are directed to immune modulation and inflammation control. As heat shock proteins are able to induce immunoregulatory T cells, we investigated the therapeutic effect of a genetic vaccine containing the mycobacterial hsp65 gene on experimental autoimmune encephalomyelitis (EAE). Although pVAXhsp65 was immunogenic for mice with EAE and downmodulated specific cytokine induction by MOG, therapy was not able to decrease clinical severity nor to modify immunologic parameters in the CNS. These results indicate that hsp65, administered as a DNA vaccine, was not therapeutic for EAE. (C) 2014 Elsevier B.V. All rights reserved.35-42engExperimental autoimmune encephalomyelitis hsp65DNA vaccineCD4+CD25+Foxp3+T cellsArtigo10.1016/j.jneuroim.2013.12.015WOS:000333730200004Acesso restrito4977572416129527